Linked Life Data

21193110

Source:http://linkedlifedata.com/resource/pubmed/id/21193110

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-1-3
pubmed:abstractText
Pharmacovigilance is an essential element of any drug treatment and considering the history of adverse events due to products used to treat inherited bleeding disorders, it should be an integral component of modern haemophilia treatment. Because inherited bleeding disorders and adverse events are rare, a multicentre, preferably multinational, adverse event reporting scheme for all clotting factor products is required. EUHASS is a European, prospective, multicentre adverse event reporting scheme in the field of inherited bleeding disorders.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1879-2472
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
127 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S22-5
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
EUHASS: The European Haemophilia Safety Surveillance system.
pubmed:affiliation
University of Sheffield, UK. m.makris@sheffield.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study